Oral administration of beta-cryptoxanthin prevents bone loss in ovariectomized rats.
The effect of beta-cryptoxanthin, a kind of carotenoid, on ovariectomy-induced bone loss was investigated. beta-cryptoxanthin was isolated from Satsuma mandarin (Citrus unshu. MARC). beta-cryptoxanthin (5 or 10 microg/100 g body weight) was orally administered once daily for 3 months to ovariectomized (OVX) rats. OVX induced a significant increase in body weight and a significant decrease in serum calcium and inorganic phosphorus concentrations as compared with those of sham-operated (control) rats. These alterations induced by OVX were significantly prevented by the administration of beta-cryptoxanthin (5 or 10 microg/100 g). The analysis using a peripheral quantitative computed tomography (pQCT) showed that OVX induced a significant decrease in mineral content and mineral density in the femoral-diaphyseal and -metaphyseal tissues and polar strength strain index in the metaphyseal tissues. These decreases were significantly prevented by the administration of beta-cryptoxanthin (5 or 10 microg/100 g). Moreover, OVX induced a significant decrease in calcium content and alkaline phosphatase activity in the femoral-diaphyseal and -metaphyseal tissues and deoxyribonucleic acid (DNA) content in the metaphyseal tissues. These decreases were significantly prevented by the administration of beta-cryptoxanthin (5 or 10 microg/100 g). This study demonstrates that beta-cryptoxanthin has a preventive effect on OVX-induced bone loss in vivo.
Uchiyama
Satoshi
S
Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Yamaguchi
Masayoshi
M
D000284:Administration, Oral; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D001835:Body Weight; D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption / Q000517:prevention & control*; D065366:Cryptoxanthins; D005260:Female; D005269:Femur / Q000033:anatomy & histology / Q000187:drug effects / Q000473:pathology; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D010052:Ovariectomy; D051381:Rats; D017208:Rats, Wistar; D024341:Xanthophylls; D019207:beta Carotene / Q000031:analogs & derivatives* / Q000494:pharmacology
D016588:Anticarcinogenic Agents; D065366:Cryptoxanthins; D024341:Xanthophylls; D019207:beta Carotene